Regeneron does not undertake any obligation ... I just had one on EYLEA and the foundation funding. Appreciate the color on the call. But just any updated thoughts on when we could think about ...

Tom Brady knows how to draw a crowd.Most notably during his NFL career, in which he won a record-breaking seven Super ...

Novo Nordisk announced it will work with the biotech Septerna to develop oral GLP-1 obesity drugs in a deal worth up to $2.2 ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said ...

Regeneron Pharmaceuticals (REGN) shares sank when the biopharma firm's earnings and revenue missed forecasts as sales of its blockbuster eye treatment, Eylea, were weaker than anticipated.

Regeneron Pharmaceuticals Inc. REGN shares are trading higher on Wednesday, recovering after a drop on Tuesday that followed the release of weaker-than-expected first quarter 2025 financial results.

Leonard Schleifer; Co-Chairman of the Board, President, Chief Executive Officer, Founder; Regeneron Pharmaceuticals Inc George Yancopoulos; Co-Chairman of the Board, President, Chief Scientific ...

April 29 (Reuters) - Regeneron's (REGN.O), opens new tab first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug Eylea, further stoking ...

Regeneron Pharmaceuticals, Inc. and Society for Science (the Society) announced that Adam Koval?ík, 19, of Dulovce, Slovakia, ...

Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year on year to $3.03 billion. Its non-GAAP profit of $8.22 per share was ...